DMOAD developments: Present and future

Bulletin of the NYU Hospital for Joint Diseases

Volumn 65, Issue 3, 2007, Pages 242-248

  Pelletier, Jean Pierre ^a   Martel Pelletier, Johanne ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMTS 5; AGGRECANASE; AGGRECANASE 2; ANTIINFLAMMATORY AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; CALCITONIN; CHONDROITIN SULFATE; COLLAGENASE 3; DIACETYLRHEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; GLUCOSAMINE SULFATE; GROWTH FACTOR; HYALURONIC ACID; LICOFELONE; METALLOPROTEINASE; NAPROXEN; PLACEBO; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ACETIC ACID DERIVATIVE; ANTHRAQUINONE DERIVATIVE; ANTIRHEUMATIC AGENT; CHONDROITIN; GLUCOSAMINE; MATRIX METALLOPROTEINASE; PYRROLE DERIVATIVE;

BODY MASS; BONE REMODELING; CARTILAGE DEGENERATION; CLINICAL EVALUATION; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; EXERCISE; HUMAN; KNEE OSTEOARTHRITIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; OSTEOLYSIS; PATHOGENICITY; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; REVIEW; RISK FACTOR; SYNOVITIS; DRUG ANTAGONISM;

ACETIC ACIDS; ANTHRAQUINONES; ANTIRHEUMATIC AGENTS; CHONDROITIN; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DISEASE PROGRESSION; DOXYCYCLINE; GLUCOSAMINE; HUMANS; HYALURONIC ACID; MATRIX METALLOPROTEINASES; OSTEOARTHRITIS; PYRROLES; RISK FACTORS;

EID: 38449105821     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Martel-Pelletier J, Lajeunesse D, Pelletier JP. Etiopathogenesis of osteoarthritis. In: Koopman WJ, Morelaid LW (eds): Arthritis & Allied Conditions. A Textbook of Rheumatology. Baltimore: Lippincott, Williams & Wilkins, 2005, pp. 2199-2226.
2. Martel-Pelletier J, Lajeunesse D, Fahmi H, et al. New thoughts on the pathophysiology of osteoarthritis: One more step toward new therapeutic targets. Curr Rheumatol Rep. 2006 Feb;8(1):30-6.
3. Pelletier JP, Martel-Pelletier J, Raynauld JP. Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: Today and tomorrow. Arthritis Res Ther. 2006;8:206. Epub 2006 Mar 21.
4. Brandt KD, Radin EL, Dieppe PA, et al. Yet more evidence that osteoarthritis is not a cartilage disease. Ann Rheum Dis. 2006 Oct;65(10):1261-4.
5. Felson DT, Goggins J, Niu J, et al. The effect of body weight on progression of knee osteoarthritis is dependent on alignment. Arthritis Rheum. 2004 Dec;50(12):3904-9.
6. Sharma L, Lou C, Felson DT, et al. Laxity in healthy and osteoarthritic knees. Arthritis Rheum. 1999 Dec;42(5):861-70.
7. Lane NE, Michel B, Bjorkengren A, et al. The risk of osteoarthritis with running and aging: a 5-year longitudinal study. J Rheumatol. 1993 Mar;20(3):461-8.
8. Martel-Pelletier J, Welsch DJ, Pelletier JP. Metalloproteases and inhibitors in arthritic diseases. In: Woolf AD (ed): Bailliè re's Best Practice & Research Clinical Rheumatology. East Sussex, United Kingdom: Baillière Tindall, 2001, pp. 805-829.
9. Glasson SS, Askew R, Sheppard B, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 2005 Mar;434(7033):644-8.
10. Stanton H, Rogerson FM, East CJ, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature. 2005 Mar;434(7033):648-52.
11. Tardif G, Pelletier JP, Hum D, et al. Differential regulation of the bone morphogenic protein antagonist chordin in human normal and osteoarthritic chondrocytes. Ann Rheum Dis. 2006;65:261-4.
12. Tardif G, Hum D, Pelletier JP, et al. Differential gene expression and regulation of the bone morphogenic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. Arthritis Rheum. 2004;50:2521-30.
13. Martel-Pelletier J, Lajeunesse D, Reboul P, et al. The role of subchondral bone in osteoarthritis. In: Sharma L, Berenbaum F (eds): Osteoarthritis: A Companion to Rheumatology. Philadelphia: Mosby Elsevier, 2007, pp. 15-32.
14. Lajeunesse D, Massicotte F, Pelletier JP, et al. Subchondral bone sclerosis in osteoarthritis: not just an innocent bystander. Modern Rheumatol. 2003;13:7-14.
15. Wilder FV, Hall BJ, Barrett JP Jr, Lemrow NB. History of acute knee injury and osteoarthritis of the knee: a prospective epidemiological assessment: the Clearwater Osteoarthrtis Study. Osteoarthritis Cartilage. 2002;10:611-6.
16. Raynauld JP, Martel-Pelletier J, Berthiaume MJ, et al. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: Correlation with clinical symptoms and radiographic changes. Arthritis Res Ther. 2005;8(1):R21. Epub 2005 Dec 30.
17. Berthiaume MJ, Raynauld JP, Martel-Pelletier J, et al. Meniscal tear and extrusion are strongly associated with the progression of knee osteoarthritis as assessed by quantitative magnetic resonance imaging. Ann Rheum Dis. 2005 Apr;64(4):556-63.
18. Felson DT, Chaisson CE, Hill CL, et al. The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med. 2001 (Apr);134(7):541-9.
19. Hunter DJ, Zhang Y, Niu J, et al. Increase in bone marrow lesions associated with cartilage loss: a longitudinal magnetic resonance imaging study of knee osteoarthritis. Arthritis Rheum. 2006 May;54(5):1529-35.
20. Raynauld JP, Martel-Pelletier J, Berthiaume MJ, et al. Correlation between bone lesion changes and cartilage volume loss in knee osteoarthritis patients as assessed by quantitative MRI over a two-year period. Ann Rheum Dis. In press, 2007.
21. Bettica P, Cline G, Hart DJ, et al. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: Longitudinal results from the Chingford study. Arthritis Rheum. 2002 Dec;46(12):3178-84.
22. Pelletier JP, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000 Oct;43(10):2339-48.
23. Fidelix TS, Soares BG, Trevisani VF. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006;(1):CD005117.
24. Dougados M, Nguyen M, Berdah L, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum. 2001 Nov;44(11):2539-47.
25. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001 Jan;357(9252):251-6.
26. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002 Oct;162(18):2113-23.
27. Bruyere O, Pavelka K, Rovati LC, et al. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause. 2004 Mar-Apr;11(2):138-43.
28. Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005 Mar;52(3):779-86.
29. Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage. 2004 Apr;12(4):269-76.
30. Reginster JY, Kahan A, Vignon E. A two-year prospective, randomized, double-blind, controlled study assessing the effect of chondroitin 4&6 sulfate (CS) on the structural progression of knee osteoarthritis: STOPP (STudy on osteoarthritis progression prevention). American College of Rheumatology Scientific Meeting 2006;(online abstract).
31. Jubb RW, Piva S, Beinat L, et al. A one-year, randomised, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract. 2003 Jul-Aug;57(6):467-74.
32. Brandt KD, Mazzuca SA, Katz BP, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum. 2005 Jul;52(7):2015-25.
33. Laufer S, Tries S, Augustin J, et al. Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H- pyrrolizine-5-yl]-acetic acid. Arzneimittelforschung. 1995 Jan;45(1):27-32.
34. Wallace JL, Carter L, McKnight W et al. ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury. Eur J Pharmacol. 1994 Dec;271(2-3):525-31.
35. Jovanovic DV, Fernandes JC, Martel-Pelletier J, et al. The in vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis, suppression of collagenase-1 and interleukin-1beta synthesis. Arthritis Rheum. 2001 Oct;44(10):2320-30.
36. Pelletier J-P, Raynauld J-P, Bias P, et al. Licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, reduces the progression of knee osteoarthritis (OA): a double blind, multicenter two-year study using quantitative MRI. Arthritis Rheum (Late-breaking abstract - Podium Presentation. Annual American College of Rheumatology Meeting) 2006;(online abstract).
37. 2δ ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes. Arthritis Rheum. 2005 Feb;52(2):488-500.
38. Pelletier JP, Lascau-Coman V, Jovanovic D, et al. Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors. J Rheumatol. 1999 Sep;26(9):2002-14.
39. Pelletier JP, Jovanovic DV, Lascau-Coman V, et al. Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocytes apoptosis and caspase 3 level. Arthritis Rheum. 2000;43:1290-9.
40. Renkiewicz R, Qiu L, Lesch C, et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum. 2003;48(6):1742-9.
41. Manicourt DH, Altman RD, Williams JM, et al. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum. 1999 Jun;42(6):1159-67.
42. Hayami T, Pickarski M, Wesolowski GA, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum. 2004 Apr;50(4):1193-206.
43. Pelletier JP, Boileau C, Brunet J, et al. The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone. 2004 Mar;34(3):527-38.